Quetmolimab Biosimilar – Anti-CX3CL1 mAb – Research Grade

Description of Quetmolimab Biosimilar - Anti-CX3CL1 mAb - Research Grade

Introduction

Quetmolimab Biosimilar, also known as Anti-CX3CL1 mAb, is a monoclonal antibody that targets the chemokine CX3CL1. It is a research grade antibody that has shown promising results in preclinical studies and is currently being investigated for its potential therapeutic applications. In this article, we will discuss the structure, activity, and potential applications of Quetmolimab Biosimilar.

Structure of Quetmolimab Biosimilar

Quetmolimab Biosimilar is a fully human IgG1 monoclonal antibody that has been engineered to specifically target CX3CL1. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region is responsible for binding to CX3CL1, while the constant region determines the antibody’s effector functions.

The amino acid sequence of Quetmolimab Biosimilar has been carefully designed to ensure high specificity and affinity for CX3CL1. It has a molecular weight of approximately 150 kDa and is glycosylated, meaning it has sugar molecules attached to it. This glycosylation is important for the antibody’s stability and function.

Activity of Quetmolimab Biosimilar

Quetmolimab Biosimilar works by binding to CX3CL1, a chemokine that plays a crucial role in inflammation and immune response. CX3CL1 is expressed on the surface of various cells, including immune cells and endothelial cells. It acts as a chemoattractant, meaning it attracts immune cells to the site of inflammation.

By binding to CX3CL1, Quetmolimab Biosimilar blocks its interaction with its receptor, CX3CR1, on immune cells. This prevents the recruitment of immune cells to the site of inflammation, thereby reducing the inflammatory response. In addition, Quetmolimab Biosimilar can also induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to eliminate CX3CL1-expressing cells.

Potential Applications of Quetmolimab Biosimilar

Quetmolimab Biosimilar has shown promising results in preclinical studies for various inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. By targeting CX3CL1, it has the potential to reduce inflammation and alleviate symptoms in these diseases.

In addition, Quetmolimab Biosimilar has also been investigated for its potential in cancer treatment. CX3CL1 has been shown to play a role in tumor growth and metastasis, and by blocking its interaction with CX3CR1, Quetmolimab Biosimilar may inhibit tumor progression. It has shown promising results in preclinical studies for various types of cancer, including breast cancer, lung cancer, and pancreatic cancer.

Furthermore, Quetmolimab Biosimilar has also been studied in combination with other therapies, such as checkpoint inhibitors, to enhance its anti-tumor activity. This combination approach has shown promising results in preclinical studies and is currently being evaluated in clinical trials.

Conclusion

Quetmolimab Biosimilar, also known as Anti-CX3CL1 mAb, is a research grade antibody that specifically targets the chemokine CX3CL1. Its unique structure and mechanism of action make it a promising candidate for the treatment of various inflammatory conditions and cancers. Further studies and clinical trials are needed to fully understand its potential and efficacy in these diseases.